pubmed-article:18559720 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0018801 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0155626 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0262926 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0961485 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0332119 | lld:lifeskim |
pubmed-article:18559720 | lifeskim:mentions | umls-concept:C0231242 | lld:lifeskim |
pubmed-article:18559720 | pubmed:issue | 2 | lld:pubmed |
pubmed-article:18559720 | pubmed:dateCreated | 2008-7-24 | lld:pubmed |
pubmed-article:18559720 | pubmed:abstractText | In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (n=6632), eplerenone-associated reduction in all-cause mortality was significantly greater in those with a history of hypertension (Hx-HTN). There were 4007 patients with Hx-HTN (eplerenone: n=1983) and 2625 patients without Hx-HTN (eplerenone: n=1336). Propensity scores for eplerenone use, separately calculated for patients with and without Hx-HTN, were used to assemble matched cohorts of 1838 and 1176 pairs of patients. In patients with Hx-HTN, all-cause mortality occurred in 18% of patients treated with placebo (rate, 1430/10 000 person-years) and 14% of patients treated with eplerenone (rate, 1058/10 000 person-years) during 2350 and 2457 years of follow-up, respectively (hazard ratio [HR]: 0.71; 95% CI: 0.59 to 0.85; P<0.0001). Composite end point of cardiovascular hospitalization or cardiovascular mortality occurred in 33% of placebo-treated patients (3029/10 000 person-years) and 28% of eplerenone-treated patients (2438/10 000 person-years) with Hx-HTN (HR: 0.82; 95% CI: 0.72 to 0.94; P=0.003). In patients without Hx-HTN, eplerenone reduced heart failure hospitalization (HR: 73; 95% CI: 0.55 to 0.97; P=0.028) but had no effect on mortality (HR: 0.91; 95% CI: 0.72 to 1.15; P=0.435) or on the composite end point (HR: 0.91; 95% CI: 0.76 to 1.10; P=0.331). Eplerenone should, therefore, be prescribed to all of the post-acute myocardial infarction patients with reduced left ventricular ejection fraction and heart failure regardless of Hx-HTN. | lld:pubmed |
pubmed-article:18559720 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:language | eng | lld:pubmed |
pubmed-article:18559720 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18559720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18559720 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18559720 | pubmed:month | Aug | lld:pubmed |
pubmed-article:18559720 | pubmed:issn | 1524-4563 | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:AliAhmedA | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:ShiHarryH | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:PittBertramB | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:KrumHenryH | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:ZannadFaiezF | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:AschermannMic... | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:ParkhomenkoAl... | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:LoveThomas... | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:NicolauJoseJ | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:SolomonHenryH | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:CardosoJosé... | lld:pubmed |
pubmed-article:18559720 | pubmed:author | pubmed-author:CorbalánRamon... | lld:pubmed |
pubmed-article:18559720 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:18559720 | pubmed:volume | 52 | lld:pubmed |
pubmed-article:18559720 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18559720 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18559720 | pubmed:pagination | 271-8 | lld:pubmed |
pubmed-article:18559720 | pubmed:dateRevised | 2010-8-20 | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:meshHeading | pubmed-meshheading:18559720... | lld:pubmed |
pubmed-article:18559720 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18559720 | pubmed:articleTitle | History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. | lld:pubmed |
pubmed-article:18559720 | pubmed:affiliation | University of Michigan, 1500 E Medical Center Dr, 3910 Taubman Center, Ann Arbor, MI 48109-0366, USA. bpitt@med.umich.edu | lld:pubmed |
pubmed-article:18559720 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18559720 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:18559720 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:18559720 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:18559720 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18559720 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18559720 | lld:pubmed |